| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 630 companies in the Biotechnology industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 6, 2026 | COAG Hemab Therapeutics Holdings, Inc. Common Stock | Ra Capital Management, L.P.53 | Director, 10% Owner | Buy | 2,840,429 | $18.39 | $52,222,945.65 | +9.9% | - | - | |
| May 5, 2026 | RLYB Rallybio Corporation | Adar1 Capital Management, LLC73 | 10% Owner | Buy | 155,905 | $13.97 | $2,178,668.31 | +7.8% | - | - | |
| May 5, 2026 | EWTX Edgewise Therapeutics, Inc. | Donovan Joanne M.49 | CMO | Sell | 55,230 | $37.88 | $2,092,062.91 | -86.3% | - | - | |
| May 4, 2026 | ARQT Arcutis Biotherapeutics, Inc. | Matsuda Masaru51 | See Remarks | Sell | 8,256 | $23.31 | $192,415.26 | -3.1% | - | - | |
| May 4, 2026 | TRDA Entrada Therapeutics, Inc. | Dowden Nathan J70 | President &COO | Sell | 15,000 | $15.33 | $229,953.00 | -7.0% | - | - | |
| May 4, 2026 | SPTX Seaport Therapeutics, Inc. Common Stock | Arch Venture Partners Xii, LLC63 | 10% Owner | Buy | 1,100,000 | $18.00 | $19,800,000.00 | +21.2% | - | - | |
| May 4, 2026 | SPRO Spero Therapeutics, Inc. | Rajavelu Esther | See Remarks | Sell | 25,240 | $2.51 | $63,352.40 | -2.5% | - | - | |
| May 4, 2026 | TRDA Entrada Therapeutics, Inc. | Sethuraman Natarajan83 | President, Research &Develop. | Sell | 25,907 | $15.39 | $398,809.77 | -10.7% | - | - | |
| May 4, 2026 | ACAD Acadia Pharmaceuticals Inc. | Kihara James62 | Principal Accounting Officer | Sell | 1,332 | $21.79 | $29,024.28 | -4.4% | - | - | |
| May 4, 2026 | ACAD Acadia Pharmaceuticals Inc. | Schneyer Mark C.59 | EVP, Chief Financial Officer | Sell | 3,506 | $21.79 | $76,395.74 | -5.0% | - | - | |
| May 4, 2026 | HOWL Werewolf Therapeutics, Inc. | Evnin Luke55 | Director | Sell | 274,619 | $0.72 | $198,309.62 | -5.0% | - | - | |
| May 1, 2026 | BLTE Belite Bio, Inc | Mata Nathan L. | Chief Scientific Officer | Sell | 1,000 | $155.78 | $155,777.84 | -3.1% | - | - | |
| May 1, 2026 | REGN Regeneron Pharmaceuticals, Inc. | Ryan Arthur F54 | Director | Sell | 100 | $705.24 | $70,523.80 | - | - | - | |
| May 1, 2026 | AVLN Avalyn Pharma Inc. Common Stock | Carroll Jill56 | Director | Buy | 277,778 | $18.00 | $5,000,004.00 | +14.6% | - | - | |
| May 1, 2026 | SYRE Spyre Therapeutics, Inc. | Burrows Scott L74 | Chief Financial Officer | Sell | 12,500 | $71.37 | $892,125.00 | -11.3% | - | - | |
| May 1, 2026 | SYRE Spyre Therapeutics, Inc. | Turtle Cameron | Chief Executive Officer | Sell | 15,000 | $71.37 | $1,070,507.00 | -0.4% | - | - | |
| May 1, 2026 | IMVT Immunovant, Inc. | Susman Robert Graham | Director | Sell | 2,502 | $27.17 | $67,979.34 | -6.4% | - | - | |
| May 1, 2026 | XERS Xeris Biopharma Holdings, Inc. | Hecht Beth47 | See Remarks | Sell | 16,667 | $6.23 | $103,805.41 | -1.4% | - | - | |
| May 1, 2026 | CTNM Contineum Therapeutics, Inc. | Lorrain Daniel S.68 | Chief Scientific Officer | Sell | 4,170 | $13.12 | $54,694.20 | -1.4% | - | - | |
| May 1, 2026 | PCVX Vaxcyte, Inc. | Wassil Jim53 | Chief Operating Officer | Sell | 2,250 | $56.83 | $127,869.75 | -1.4% | - | - | |
| May 1, 2026 | TNGX Tango Therapeutics, Inc. | Crystal Adam77 | President, R&D | Sell | 27,000 | $21.23 | $573,097.33 | -10.4% | - | - | |
| May 1, 2026 | SYRE Spyre Therapeutics, Inc. | Sloan Sheldon | Chief Medical Officer | Sell | 78,333 | $71.50 | $5,600,701.16 | -35.1% | - | - | |
| May 1, 2026 | AVLN Avalyn Pharma Inc. Common Stock | Sr One Capital Management, LLC52 | 10% Owner | Buy | 555,555 | $18.00 | $9,999,990.00 | +20.2% | - | - | |
| May 1, 2026 | GLUE Monte Rosa Therapeutics, Inc. | Warmuth Markus | President &CEO | Sell | 5,467 | $18.92 | $103,446.57 | -0.9% | - | - | |
| May 1, 2026 | NRIX Nurix Therapeutics, Inc. | Ring Christine77 | Chief Legal Officer | Sell | 5,394 | $16.76 | $90,406.68 | -16.9% | - | - |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.